Arbaclofen placarbil

Arbaclofen placarbil

Clinical data
Pregnancy category	N/A
ATC code	none
Legal status
Legal status	Development terminated
Identifiers
IUPAC name (3R)-3-(4-chlorophenyl)-4-[[[(1S)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy]carbonyl]amino]butanoic acid
CAS Number	847353-30-4
PubChem CID	11281011
ChemSpider	9456008
UNII	W89H91R7VX
KEGG	D08861 Y
ChEMBL	ChEMBL2107312 Y
CompTox Dashboard (EPA)	DTXSID40233754
ECHA InfoCard	100.221.150
Chemical and physical data
Formula	C19H26ClNO6
Molar mass	399.87 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C
InChI InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1 Key:JXTAALBWJQJLGN-KSSFIOAISA-N

Arbaclofen placarbil (/ɑːrˈbækloʊfɛn pləˈkɑːrbɪl/ ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.

It is being developed as an addiction medicine to treat alcoholism. It is also studied as a potential therapeutic for some autistic subjects.

See also

• Gabapentin enacarbil
• Lesogaberan